Nuveen
STRO icon

Nuveen’s Sutro Biopharma STRO Stock Holding History

Nuveen’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.58M Buy
+167,997
New +$5.24M ﹤0.01% 2036
2025
Q2 		– Sell
-29,090
Closed -$189K – 3406
2025
Q1 		$189K Sell
29,090
-103,288
-78% -$1.63M ﹤0.01% 3140
2024
Q4 		$2.44M Buy
132,378
+12,416
+10% +$379K ﹤0.01% 2293
2024
Q3 		$4.15M Buy
119,962
+29,418
+32% +$1.15M ﹤0.01% 2075
2024
Q2 		$2.65M Buy
90,544
+56,781
+168% +$2.25M ﹤0.01% 2247
2024
Q1 		$1.91M Buy
33,763
+12,190
+57% +$538K ﹤0.01% 2426
2023
Q4 		$925K Buy
21,573
+358
+2% +$11.4K ﹤0.01% 2764
2023
Q3 		$736K Sell
21,215
-147
-0.7% -$6.4K ﹤0.01% 2700
2023
Q2 		$993K Sell
21,362
-2,484
-10% -$124K ﹤0.01% 2663
2023
Q1 		$1.1M Buy
23,846
+3,033
+15% +$192K ﹤0.01% 2577
2022
Q4 		$1.68M Sell
20,813
-2,247
-10% -$156K ﹤0.01% 2470
2022
Q3 		$1.28M Sell
23,060
-87
-0.4% -$5.15K ﹤0.01% 2635
2022
Q2 		$1.21M Buy
23,147
+4,534
+24% +$253K ﹤0.01% 2701
2022
Q1 		$1.48M Buy
18,613
+393
+2% +$37.4K ﹤0.01% 2651
2021
Q4 		$2.71M Sell
18,220
-17,606
-49% -$3.15M ﹤0.01% 2413
2021
Q3 		$6.77M Sell
35,826
-4,794
-12% -$912K ﹤0.01% 2054
2021
Q2 		$7.55M Buy
40,620
+2,097
+5% +$410K ﹤0.01% 2026
2021
Q1 		$8.77M Buy
38,523
+12,091
+46% +$2.87M ﹤0.01% 1874
2020
Q4 		$5.74M Buy
26,432
+15,488
+142% +$2.56M ﹤0.01% 1997
2020
Q3 		$1.1M Buy
10,944
+5,870
+116% +$555K ﹤0.01% 2644
2020
Q2 		$393K Buy
5,074
+1,130
+29% +$108K ﹤0.01% 2981
2020
Q1 		$403K Buy
3,944
+1,220
+45% +$128K ﹤0.01% 2846
2019
Q4 		$300K Sell
2,724
-99
-4% -$10.2K ﹤0.01% 3012
2019
Q3 		$257K Buy
2,823
+1,227
+77% +$124K ﹤0.01% 3079
2019
Q2 		$182K Buy
+1,596
New +$176K ﹤0.01% 3188

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Nuveen's STRO Position: Q2 2026 in Review

Nuveen opened a new position in Sutro Biopharma (STRO) in Q2 2026: 167,997 shares worth $5.58M. The stake represents ﹤0.01% of the portfolio and ranks #2036 among its holdings. This is a return to the name: Nuveen previously reported a position in STRO as recently as Q1 2025.

Nuveen first reported a position in STRO in Q2 2019 and has held it in 25 quarters since. The position peaked at $8.77M in Q1 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Nuveen held 167,997 shares of Sutro Biopharma worth $5.58M as of Q2 2026.
  • Sutro Biopharma was a new Nuveen position in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2036 holding.
  • Nuveen first reported a position in Sutro Biopharma in Q2 2019 and has held it in 25 quarters since.
  • Nuveen's Sutro Biopharma position peaked at $8.77M in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.